A Case of Advanced Lung Adenocarcinoma in an Elderly Patient Who Maintained Responsiveness after Discontinuation of Immune Checkpoint Inhibitors
An 81-year-old woman was admitted to our hospital because of an abnormal opacity on the chest radiograph. She was diagnosed with cT3N3M1a, Stage ⅣA left lower lung lobe adenocarcinoma, and the PD-L1(22C3)expression was high (tumor proportion score[TPS]: 100%). She was administered with pembrolizumab monotherapy because her performance status(PS)was PS 1. After 4 courses, she had a partial response(PR), but her treatment had to be discontinued because of cutaneous adverse effects. After 6 months, the tumor regrew, and atezolizumab monotherapy was provided. Another cutaneous adverse event occurred, and treatment was discontinued again. However, a complete response(CR)was maintained for approximately 2 years and 6 months after discontinuation of treatments.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 50(2023), 11 vom: 31. Nov., Seite 1231-1233 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Suganuma, Akira [VerfasserIn] |
|---|
| Themen: |
Antineoplastic Agents, Immunological |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 11.12.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM365477893 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365477893 | ||
| 003 | DE-627 | ||
| 005 | 20231227132242.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM365477893 | ||
| 035 | |a (NLM)38056882 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Suganuma, Akira |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Case of Advanced Lung Adenocarcinoma in an Elderly Patient Who Maintained Responsiveness after Discontinuation of Immune Checkpoint Inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a An 81-year-old woman was admitted to our hospital because of an abnormal opacity on the chest radiograph. She was diagnosed with cT3N3M1a, Stage ⅣA left lower lung lobe adenocarcinoma, and the PD-L1(22C3)expression was high (tumor proportion score[TPS]: 100%). She was administered with pembrolizumab monotherapy because her performance status(PS)was PS 1. After 4 courses, she had a partial response(PR), but her treatment had to be discontinued because of cutaneous adverse effects. After 6 months, the tumor regrew, and atezolizumab monotherapy was provided. Another cutaneous adverse event occurred, and treatment was discontinued again. However, a complete response(CR)was maintained for approximately 2 years and 6 months after discontinuation of treatments | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 700 | 1 | |a Sakaguchi, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Kimoto, Masanobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kosaka, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazaki, Yoshitaka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 50(2023), 11 vom: 31. Nov., Seite 1231-1233 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:11 |g day:31 |g month:11 |g pages:1231-1233 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 11 |b 31 |c 11 |h 1231-1233 | ||